131 related articles for article (PubMed ID: 31620234)
21. Metabolism of SKLB-TB1001, a Potent Antituberculosis Agent, in Animals.
Xiong L; Gao C; Shi YJ; Tao X; Peng CT; Rong J; Liu KL; Lei Q; Zhang YW; Wang NY; Yu LT
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686156
[TBL] [Abstract][Full Text] [Related]
22. Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening.
Gao Y; Xie J; Tang R; Yang K; Zhang Y; Chen L; Li H
Bioorg Chem; 2019 Apr; 85():168-178. PubMed ID: 30616098
[TBL] [Abstract][Full Text] [Related]
23. Virtual Screening of Small Molecular Inhibitors against DprE1.
Zhang G; Guo S; Cui H; Qi J
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447
[TBL] [Abstract][Full Text] [Related]
24. Effects of deuteration on transamination and oxidation of hyperpolarized
Funk AM; Wen X; Hever T; Maptue NR; Khemtong C; Sherry AD; Malloy CR
J Magn Reson; 2019 Apr; 301():102-108. PubMed ID: 30861456
[TBL] [Abstract][Full Text] [Related]
25. 8-cyanobenzothiazinone analogs with potent antitubercular activity.
Zhang G; Sheng L; Hegde P; Li Y; Aldrich CC
Med Chem Res; 2021; 30(2):449-458. PubMed ID: 33462533
[TBL] [Abstract][Full Text] [Related]
26. Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis.
Gao C; Peng C; Shi Y; You X; Ran K; Xiong L; Ye TH; Zhang L; Wang N; Zhu Y; Liu K; Zuo W; Yu L; Wei Y
Sci Rep; 2016 Jul; 6():29717. PubMed ID: 27405961
[TBL] [Abstract][Full Text] [Related]
27. Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.
Manina G; Pasca MR; Buroni S; De Rossi E; Riccardi G
Curr Med Chem; 2010; 17(27):3099-108. PubMed ID: 20629622
[TBL] [Abstract][Full Text] [Related]
28. Crystallographic evidence for unintended benzisothiazolinone 1-oxide formation from benzothiazinones through oxidation.
Eckhardt T; Goddard R; Lehmann C; Richter A; Sahile HA; Liu R; Tiwari R; Oliver AG; Miller MJ; Seidel RW; Imming P
Acta Crystallogr C Struct Chem; 2020 Sep; 76(Pt 9):907-913. PubMed ID: 32887862
[TBL] [Abstract][Full Text] [Related]
29. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
[TBL] [Abstract][Full Text] [Related]
30. Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme.
Karan S; Kashyap VK; Shafi S; Saxena AK
J Mol Model; 2017 Aug; 23(8):241. PubMed ID: 28744747
[TBL] [Abstract][Full Text] [Related]
31. Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1: state of art.
Buroni S; Pasca MR; de Jesus Lopes Ribeiro AL; Degiacomi G; Molteni E; Riccardi G
Appl Microbiol Biotechnol; 2012 May; 94(4):907-16. PubMed ID: 22526781
[TBL] [Abstract][Full Text] [Related]
32. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
[TBL] [Abstract][Full Text] [Related]
33. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity.
Panda M; Ramachandran S; Ramachandran V; Shirude PS; Humnabadkar V; Nagalapur K; Sharma S; Kaur P; Guptha S; Narayan A; Mahadevaswamy J; Ambady A; Hegde N; Rudrapatna SS; Hosagrahara VP; Sambandamurthy VK; Raichurkar A
J Med Chem; 2014 Jun; 57(11):4761-71. PubMed ID: 24818517
[TBL] [Abstract][Full Text] [Related]
34. Current Affairs, Future Perspectives of Tuberculosis and Antitubercular Agents.
Gawad J; Bonde C
Indian J Tuberc; 2018 Jan; 65(1):15-22. PubMed ID: 29332642
[TBL] [Abstract][Full Text] [Related]
35. Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis.
Piton J; Vocat A; Lupien A; Foo CS; Riabova O; Makarov V; Cole ST
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012754
[TBL] [Abstract][Full Text] [Related]
36.
Borthwick JA; Alemparte C; Wall I; Whitehurst BC; Argyrou A; Burley G; de Dios-Anton P; Guijarro L; Monteiro MC; Ortega F; Suckling CJ; Pichel JC; Cacho M; Young RJ
J Med Chem; 2020 Mar; 63(5):2557-2576. PubMed ID: 31922409
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of deuterium-labeled crizotinib, a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
Ao W; Li Y; Zhang Y
J Labelled Comp Radiopharm; 2018 Dec; 61(14):1036-1042. PubMed ID: 30118545
[TBL] [Abstract][Full Text] [Related]
38. Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose.
Mikusová K; Huang H; Yagi T; Holsters M; Vereecke D; D'Haeze W; Scherman MS; Brennan PJ; McNeil MR; Crick DC
J Bacteriol; 2005 Dec; 187(23):8020-5. PubMed ID: 16291675
[TBL] [Abstract][Full Text] [Related]
39. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
40. An unexpected role for the active site base in cofactor orientation and flexibility in the copper amine oxidase from Hansenula polymorpha.
Plastino J; Green EL; Sanders-Loehr J; Klinman JP
Biochemistry; 1999 Jun; 38(26):8204-16. PubMed ID: 10387066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
